Laurence de Schoulepnikoff
Geschäftsführer bei OSE IMMUNOTHERAPEUTICS
Aktive Positionen von Laurence de Schoulepnikoff
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Geschäftsführer | 16.01.2022 | - |
| Corporate Officer/Principal | 20.12.2021 | 16.01.2022 | |
| Swiss Healthcare Licensing Group | Direktor/Vorstandsmitglied | - | - |
Tridek-One Therapeutics SAS
 Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Vorstandsvorsitzender | - | - |
Karriereverlauf von Laurence de Schoulepnikoff
Ehemalige bekannte Positionen von Laurence de Schoulepnikoff
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Geschäftsführer | 01.01.2019 | - |
Ausbildung von Laurence de Schoulepnikoff
| École Polytechnique Fédérale de Lausanne | Graduate Degree |
Statistik
International
| Schweiz | 4 |
| Frankreich | 3 |
Operativ
| Chief Operating Officer | 2 |
| Corporate Officer/Principal | 1 |
| Graduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| OSE IMMUNOTHERAPEUTICS | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Health Technology |
| Swiss Healthcare Licensing Group | |
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Commercial Services |
